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Early onset hereditary motor and sensory neuropathies are rare disorders encompassing congenital hypomyelinating neuropathy
with disease onset in the direct post-natal period and Dejerine–Sottas neuropathy starting in infancy. The clinical spectrum,
however, reaches beyond the boundaries of these two historically deﬁned disease entities. De novo dominant mutations in
PMP22, MPZ and EGR2 are known to be a typical cause of very early onset hereditary neuropathies. In addition, mutations in
several other dominant and recessive genes for Charcot–Marie–Tooth disease may lead to similar phenotypes. To estimate
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neuropathies, we selected a heterogeneous cohort of 77 unrelated patients who presented with symptoms of peripheral neur-
opathy within the ﬁrst year of life. The majority of these patients were isolated in their family. We performed systematic
mutation screening by means of direct sequencing of the coding regions of 11 genes: MFN2, PMP22, MPZ, EGR2, GDAP1,
NEFL, FGD4, MTMR2, PRX, SBF2 and SH3TC2. In addition, screening for the Charcot–Marie–Tooth type 1A duplication on
chromosome 17p11.2-12 was performed. In 35 patients (45%), mutations were identiﬁed. Mutations in MPZ, PMP22 and EGR2
were found most frequently in patients presenting with early hypotonia and breathing difﬁculties. The recessive genes FGD4,
PRX, MTMR2, SBF2, SH3TC2 and GDAP1 were mutated in patients presenting with early foot deformities and variable delay
in motor milestones after an uneventful neonatal period. Several patients displaying congenital foot deformities but an other-
wise normal early development carried the Charcot–Marie–Tooth type 1A duplication. This study clearly illustrates the genetic
heterogeneity underlying hereditary neuropathies with infantile onset.
Keywords: early onset hereditary neuropathies; congenital hypomyelinating neuropathy; Dejerine–Sottas neuropathy;
genotype–phenotype correlations; Charcot–Marie–Tooth disease
Abbreviations: EGR2 = early growth response 2; FGD4 = FYVE, RhoGEF, and PH domain-containing protein 4;
GDAP1 = ganglioside-induced differentiation-associated protein 1; MFN2 = mitofusin 2; MPZ = myelin protein zero;
MTMR2 = myotubularin-related protein 2; NEFL = neuroﬁlament light chain; PMP22 = peripheral myelin protein 22; PRX = periaxin;
SBF2 = set-binding factor 2; SH3TC2 = SH3 domain and tetratricopeptide repeat domain 2.
Introduction
Hereditary motor and sensory neuropathies with onset in infancy
are rare disorders that were ﬁrst described by Dejerine and Sottas,
1893 in the late 19th century as a separate disease, distinct from
the more commonly occurring Charcot–Marie–Tooth neuropathy
(Gabreels-Festen, 2002; Plante-Bordeneuve and Said, 2002).
Today, we know that these early onset hereditary neuropathies
are not a single entity but rather represent a broad clinical and
genetic spectrum of disorders that is still incompletely understood
(Ryan and Ouvrier, 2005).
Presenting symptoms in the neonate can be severe and often
include hypotonia and respiratory insufﬁciency (Phillips et al.,
1999; Smit et al., 2008). In other patients, clinical presentation
consists of early foot deformities, delay in early motor milestones,
distal sensory loss and weakness with progressive gait difﬁculties
(Plante-Bordeneuve and Said, 2002; Wilmshurst et al., 2003;
Burns et al., 2009). These early and severely affected patients
are often isolated in their family, obscuring the inheritance pattern;
either de novo mutations in dominant genes or recessive alleles
inherited from unaffected parents are at play (Gabreels-Festen,
2002; Plante-Bordeneuve and Said, 2002; Parman et al., 2004).
Two historically described forms have remained in current litera-
ture, although they are now known to represent elements of the
broader disease spectrum of demyelinating neuropathies rather
than distinct entities (Gabreels-Festen, 2002, 2005; Scherer,
2006). These are congenital hypomyelinating neuropathy with dis-
ease onset in the direct post-natal period and Dejerine–Sottas
neuropathy, starting in infancy. Typically, de novo mutations in
myelin protein zero (MPZ), peripheral myelin protein 22
(PMP22) and early growth response 2 (EGR2) are described as
the cause of congenital hypomyelinating neuropathy and
Dejerine–Sottas neuropathy. Clinical and genetic variability of her-
editary motor and sensory neuropathy reaches beyond these
boundaries however.
The currently understood genetic spectrum of early onset
hereditary motor and sensory neuropathy is very heterogeneous,
including both dominant and recessive mutations in multiple genes
(Ryan and Ouvrier, 2005). As already mentioned, de novo and
occasionally also inherited dominant mutations in EGR2, MPZ and
PMP22 may occur (Plante-Bordeneuve and Said, 2002; Smit et al.,
2008). Recessive mutations in myotubularin-related protein 2
(MTMR2), set-binding factor 2 (SBF2) and FYVE, RhoGEF, and
PH domain-containing protein 4 (FGD4) are typically found in
patients with redundant myelin loops or myelin outfoldings on
sural nerve biopsies (Bolino et al., 2000; Nelis et al., 2002a;
Azzedine et al., 2003; Fabrizi et al., 2009). Recessive mutations
in periaxin (PRX), SH3 domain and tetratricopeptide repeat
domain 2 (SH3TC2) and ganglioside-induced differentiation-
associated protein 1 (GDAP1) are also associated with very early
disease onset (Nelis et al., 2002b; Takashima et al., 2002;
Senderek et al., 2003). Mutations in mitofusin 2 (MFN2),
GDAP1, EGR2 and neuroﬁlament light chain (NEFL) can behave
both as dominant and recessive traits (Timmerman et al., 1999;
Nicholson et al., 2008; Yum et al., 2009; Zimon et al., 2011).
Since many patients still remain without a molecular diagnosis,
the above-mentioned list of genes is by no means exhaustive.
The majority of the early onset hereditary neuropathies repre-
sent demyelinating phenotypes with sometimes profoundly slowed
motor nerve conduction velocities, indicative of severe demyelin-
ation or even amyelination. Noteworthy examples are PRX and
FGD4 mutation carriers (Takashima et al., 2002; Fabrizi et al.,
2009) and also congenital onset forms with mutations in MPZ,
PMP22 and EGR2 (Gabreels-Festen, 2002). Nerve conduction
studies in MTMR2, SBF2, SH3TC2 and NEFL mutation carriers
typically also show slowed nerve conduction velocity in the
demyelinating range (Nelis et al., 2002a; Azzedine et al., 2003;
Senderek et al., 2003; Parman et al., 2004; Yum et al., 2009).
In addition to the demyelinating phenotypes, severe early
onset axonal neuropathies can be due to MFN2 or GDAP1
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In very young children presenting with neuropathy in the ab-
sence of a remarkable familial history, acquired causes of periph-
eral neuropathy such as inﬂammatory neuropathies, toxic causes
and nutritional deﬁciencies have to be considered. The disease
history and electrophysiology may provide hints in that direction.
Acquired causes, however, are proportionally less common than
hereditary causes (Connolly, 2001; Wilmshurst et al., 2003). More
often, peripheral neuropathies in very young children may be seen
as part of a syndromic (metabolic) hereditary disorder. Although
other clinical features than those of the peripheral neuropathy
usually dominate the phenotype, severe demyelinating neuropathy
leading to motor development delay may be observed as the initial
and only clinical sign in these disorders (Wilmshurst et al., 2003;
Ryan and Ouvrier, 2005; Scherer, 2006; Landrieu et al., 2011).
Detailed electrophysiological testing is essential to conﬁrm the
clinical diagnosis and further subdivide patients into demyelinating
and axonal phenotypes. Performing such examinations is challen-
ging in very young children, and normal values vary signiﬁcantly in
the ﬁrst 5 years of life due to ongoing maturation of the PNS and
limb growth. For this reason, results of nerve conduction studies
must be interpreted with utmost caution (Garcia et al., 2000;
Wilmshurst et al., 2003).
In general, the need for diagnostic sural nerve biopsies has dras-
tically decreased due to the extensive knowledge of the various
genetic causes of hereditary neuropathies and the increasing avail-
ability of molecular testing. However, in the speciﬁc case of early
onset neuropathies, nerve biopsies may still be diagnostically
meaningful in selected patients (Wilmshurst et al., 2003).
Hereditary neuropathies are most often of mixed motor and
sensory type, both in adults and children. Some forms of heredi-
tary motor neuropathy and hereditary sensory and autonomic
neuropathy can start in infancy as well (Dierick et al., 2008;
Rotthier et al., 2009). These subforms can be distinguished
through careful analysis of clinical presentation, electrophysiology
and if possible neuropathology. As an important differential diag-
nosis, Infantile spinal muscular atrophy with respiratory distress
type 1 (SMARD1) (spinal muscular atrophy with repiratory distress
type 1) due to mutations in immunoglobulin mu binding protein 2
(IGHMBP2) should be ruled out because these patients may
initially be diagnosed as early onset hereditary motor sensory
neuropathy due to very low motor nerve conduction velocities in
the upper and lower limbs (Pitt et al., 2003). Additional assess-
ment of at least one sensory nerve that is usually normal in these
patients may help to distinguish this disorder from typical early
onset hereditary motor sensory neuropathy 1.
Since the ﬁrst description by Dejerine and Sottas, many detailed
studies have been published on clinical, electrophysiological and
neuropathological aspects of early onset hereditary neuropathies
(Dejerine and Sottas, 1893). Molecular genetic studies so far have
not focused extensively on systematic genetic screenings but
rather on single patient reports, smaller patient series or gene
identiﬁcation studies. These studies offer only a partial view on
the genetic variability and the correlation with the clinical pheno-
types of childhood neuropathies.
Early onset neuropathies pose a particular diagnostic challenge
both to the treating child neurologist confronted with often se-
verely affected patients and to geneticists seeking to provide mo-
lecular diagnosis and appropriate genetic counselling.
In the current study, we report on the ﬁndings from the sys-
tematic screening of 11 relevant genes in a cohort of 77 unrelated
patients with presumed hereditary motor and sensory neuropathy
with onset in the ﬁrst year of life. Several of these patients have
been reported before, either in smaller case reports or as part of
gene identiﬁcation studies. Patients presenting with pure heredi-
tary motor neuropathy or hereditary sensory and autonomic neur-
opathy have been studied previously and were therefore not
included (Dierick et al., 2008; Rotthier et al., 2009). These geno-
type–phenotype correlations provide important insights that are of
particular relevance in the context of molecular diagnostics of rare
hereditary neuropathies with an early disease onset.
Patients and methods
Patient cohort
In this study, 77 unrelated index patients were included who presented
with symptoms of motor and sensory neuropathy within the ﬁrst year
of life. In order to grasp the full spectrum of phenotypes, we did not
apply exclusion criteria regarding electrophysiology, inheritance pat-
tern, associated clinical features or neuropathology. Presenting symp-
toms varied widely ranging from early neonatal hypotonia with
feeding and breathing difﬁculties over progressive delay of motor mile-
stones to early foot deformities in the ﬁrst 12 months of life. A diag-
nosis of demyelinating neuropathy was made for 45 patients and
axonal neuropathy for 15 patients. For the remaining 17 patients,
no clear distinction could be made. Detailed electrophysiology was
available for 50 patients. For a total of 29 patients, neuropathological
examination of a sural nerve biopsy was performed. In total, 61 pa-
tients were isolated in their family, in 10 patients a dominantly in-
herited phenotype was seen in the family and in six patients familial
history was suggestive of a recessive trait. For 21 out of the 77 index
patients consanguinity was noted; 18 of these were isolated in their
family.
Patients were referred for genetic diagnosis from various European
countries, the Middle East and the USA and were clinically evaluated
by neuro-paediatricians with expertise in the ﬁeld of rare neuromus-
cular disorders. Parents or legal representatives of all patients signed
an informed consent form prior to enrolment. The local institutional
review boards approved the study.
Mutation screening
Genomic DNA was extracted by means of standard protocols from
blood samples obtained from patients, healthy unrelated controls
and, if available, family members. The coding regions and exon–
intron boundaries of 11 genes (MFN2, PMP22, MPZ, EGR2, GDAP1,
NEFL, FGD4, MTMR2, PRX, SBF2 and SH3TC2) were polymerase
chain reaction ampliﬁed using primer oligonucleotides designed with
Primer3 (Rozen and Skaletsky, 2000) Primer sequences and poly-
merase chain reaction conditions are available on request.
Polymerase chain reaction products were puriﬁed with the Exonu-
clease I-Shrimp Alkaline Phosphatase enzymes (USB). Mutation screen-
ing was performed by bidirectional sequencing using the BigDye
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were electrophoretically separated on an ABI3730xl DNA Analyser
(Applied Biosystems). Sequence analysis was performed with the
SeqMan
TMII (DNASTAR Inc.) programme. The nucleotide numbering
was based on the published online protein and messenger RNA seq-
uence of the respective genes (www.ncbi.nlm.nih.gov). The conven-
tions of the Human Genome Variation Society nomenclature (http://
www.hgvs.org/mutnomen) were used for the description of the iden-
tiﬁed mutations. Sequence variants were conﬁrmed by an independent
polymerase chain reaction and sequencing of the original or new stock
DNA samples. Segregation of the mutations was performed when
DNA samples of family members were available. For newly identiﬁed
mutations, a minimum of 360 control chromosomes were screened.
Copy number variation studies
The Multiplex Amplicon Quantiﬁcation technique was applied
(Sleegers et al., 2006) in order to investigate the presence of patho-
genic copy number variations on the second allele in patients with
heterozygous variations in MTMR2 and PRX. The same technique
was used to screen for the CMT1A duplication/HNPP deletion in the
17p11.2-12 region.
Multiplex amplicon quantiﬁcation consists of a multiplex polymerase
chain reaction ampliﬁcation of ﬂuorescently labelled target and control
amplicons, followed by fragment analysis on an ABI3730 DNA
Analyser (Applied Biosystems). In this assay, target amplicons are
located in and around the exons of the corresponding genes and
eight control amplicons are located at randomly selected genomic pos-
itions outside the corresponding target regions and other known copy
number variations. These amplicons were polymerase chain reaction
ampliﬁed in a single reaction containing 20ng of genomic DNA. Peak
areas of the target amplicons were normalized to these of the control
amplicons. Comparison of normalized peak areas between patients
and reference individuals resulted in a dosage quotient for each
target amplicon, calculated by the Multiplex Amplicon Quantiﬁcation
software package (www.multiplicon.com). Dosage quotient values
50.75 were considered indicative for a deletion.
To further conﬁrm an identiﬁed partial duplication of PMP22,
the commercially available Multiplex Ligation-dependant Probe
Ampliﬁcation kit (P033-CMT1) was used. The same technique was
used to check for additional partial deletions of MFN2 (P143-MFN2-
MPZ). Manufacturer’s instructions were applied (MRC).
Results
Genetic ﬁndings
Extensive mutation screening of 11 genes in a large cohort of 77
unrelated patients with neuropathy with onset in the ﬁrst year of
life revealed pathogenic sequence variants in 35 patients, repre-
senting 45% of the total cohort. Sequence variants were found in
all screened genes. The genetic ﬁndings are presented per gene of
interest in Table 1 and mutation frequencies per gene are shown
in Fig. 1.
Some patients have been reported previously as part of gene
identiﬁcation studies or smaller case series; the relevant references
are provided in Table 1 (Raeymaekers et al., 1991; Nelis et al.,
1994, 2002b; Sorour et al., 1997; Timmerman et al., 1999;
Ceuterick-de Groote et al., 2001; Takashima et al., 2002;
Senderek et al., 2003; Stendel et al., 2007; Fabrizi et al., 2009).
A total of ﬁve patients carried a de novo heterozygous mutation
in MPZ, EGR2, PMP22 or MFN2. Four isolated patients were het-
erozygous for mutations in NEFL or MPZ, the CMT1A duplication
or a partial PMP22 duplication; for these, however, the de novo
character could not be conﬁrmed due to lack of DNA samples
from additional family members. Mutations in MPZ and the
CMT1A duplication were transmitted as a dominant trait in ﬁve
patients; 20 patients inherited recessive mutations in GDAP1,
MTMR2, SBF2, FGD4, PRX or SH3TC2 from their unaffected par-
ents. In one isolated patient (CMT-756.01), a novel heterozygous
Arg400Pro mutation in MFN2 was identiﬁed. Low levels of the
same mutant allele in the electropherogram of the unaffected
mother suggest a parental mosaicism for this mutation. This mu-
tation targets a highly conserved amino acid and is probably
damaging for the protein as predicted by a high Polyphen2
score (Adzhubei et al., 2010).
Additional Multiplex Amplicon Quantiﬁcation and Multiplex
Ligation-dependant Probe Ampliﬁcation assays in the patients
with heterozygous sequence variants in PRX, MTMR2 and
MFN2 did not provide evidence for partial intragenic deletions.
Clinical ﬁndings
Detailed clinical and electrophysiological ﬁndings in patients carry-
ing pathogenic mutations are presented in Tables 2 and 3. The
data from the nerve conduction studies have to be interpreted
with caution since the age at which electrophysiological testing
was performed varied widely among patients making the applica-
tion of one standardized set of normal values impossible (Garcia
et al., 2000).
All patients with pathogenic mutations presented with symp-
toms suggestive of peripheral neuropathy within the ﬁrst year
of life. Presenting symptoms were nonetheless variable. A small
number of patients present very soon after birth with hypotonia,
occasionally associated with breathing difﬁculties. A second
group of patients present with congenital or very early foot defor-
mities often in combination with progressive delay in motor mile-
stones in the ﬁrst year of life, after an otherwise normal neonatal
period.
Discussion
We performed a broad and systematic genetic screening in a large
cohort of patients presenting with infantile onset hereditary neur-
opathy. Overall, a molecular diagnosis could be reached in 45% of
patients by screening for mutations in a total of 11 genes and for
the CMT1A duplication in the 17p11.2-12 region (Fig. 1).
Although the overall mutation frequency was high, the genetic
heterogeneity is extensive resulting in a diagnostic yield per
gene that rarely exceeds more than a few per cent of the total
cohort. Both dominant and recessive mutations are implemented
in this age group with the recessive ones being slightly more
prevalent in our series (20 index patients versus 15). Most
common were the CMT1A duplication and mutations in MPZ,
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As far as dominant mutations are concerned, these are often
de novo events, as was previously described in patients with con-
genital hypomyelinating neuropathy or Dejerine–Sottas neur-
opathy (Gabreels-Festen, 2002; Plante-Bordeneuve and Said,
2002). However, we also show a few cases of inherited dominant
traits (mainly for MPZ and the CMT1A duplication) that can also
produce severe early onset phenotypes in some patients, in spite
of the generally milder phenotype in the other family members
(Raeymaekers et al., 1991; Nelis et al., 1994; Sorour et al., 1997).
These young patients represent the far end of the disease spec-
trum associated with the various demyelinating types of classical
Charcot–Marie–Tooth disease. In these instances, the familial his-
tory is useful in guiding the molecular testing, but one has to be
equally alert for such mutations in isolated patients. It is important
to note that more mildly affected or even asymptomatic individ-
uals are still at risk of having offspring with a more severe onset
phenotype. This was recently shown for other dominantly in-
herited Charcot–Marie–Tooth variants caused by mutations in
TRPV4 and GDAP1 (Zimon et al., 2010, 2011). There are also
reports in the literature of transmitted cases of severe Charcot–
Marie–Tooth phenotypes (Smit et al., 2008). For the dominant
genes, mutations in MPZ were equally frequent as patients carry-
ing the CMT1A duplication. In the particular case of patient
CMT-756.01 with the novel heterozygous Arg400Pro mutation
in MFN2, a possible parental mosaicism was identiﬁed. This ﬁnd-
ing has important implications towards genetic counselling and
emphasizes the importance of critical analysis of DNA samples of
clinically unaffected parents.
Mutations in recessive genes are often found in isolated pa-
tients, many of whom are the product of a consanguineous union.
The cohort used for this study contained a total of 21 index pa-
tients from such consanguineous families; this may have inﬂuen-
ced the total frequency of recessive forms to some extent. It is,
however, important to note that of the 20 index patients with
recessive mutations, at least ﬁve stem from non-consanguineous
European families (PN-1101.2, CMT-191.01, CMT-192.01,
PN-1321.1 and PN-754.3). Therefore, a certain degree of
suspicion for recessive forms of neuropathy is warranted in
non-consanguineous populations, especially since the inheritance
pattern would not be evident in small kinships.
Overall, we found SH3TC2 to be the most commonly mutated
recessive gene in this cohort. SH3TC2 is associated with variable
phenotypes and is known to be relatively common among the
recessive Charcot–Marie–Tooth variants (Houlden et al., 2009).
From a phenotypic point of view, it is important to note that
even within this group of patients with neuropathy with a very
early disease onset, there is considerable clinical variability. A few
different subgroups of patients can be delineated that in turn cor-
respond to selected subsets of the genes screened in this study
(Fig. 2).
The ﬁrst group comprises genuinely congenital onset pheno-
types presenting soon after birth with symptoms such as hypo-
tonia and breathing difﬁculties. In these patients, de novo
mutations in MPZ, EGR2 and PMP22 are typically found (Phillips
et al., 1999; Timmerman et al., 1999; Ceuterick-de Groote et al.,
2001). In addition, we identiﬁed a heterozygous NEFL mutation
that was previously reported to cause severe early onset pheno-
types (Yoshihara et al., 2002). More surprisingly, we detected a
previously unreported partial duplication of exon 4 of PMP22 in
an isolated patient presenting with a congenital onset phenotype.
Although the vast majority of copy number variations in the
17p11.2-12 region is the recurrent 1.4Mb CMT1A duplication/
deletion, some atypical non-recurrent copy number variations
have been reported including the entire PMP22 gene, single
PMP22 exons or regulatory sequences (Zhang et al., 2010).
The de novo character of this variation in patient CMT-127.04
could not be proven due to lack of the parent’s DNA samples; it
may therefore still be a benign polymorphism. However, this
PMP22 exonic duplication may well be pathogenic through
such mechanisms as exon shufﬂing or insertional translocation
Figure 1 Gene distribution among 35 patients with pathogenic mutations out of a cohort of 77 unrelated index patients.
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patient CMT-127.04. To date, this partial duplication of exon 4
had not been encountered in 4400 samples that were screened
for diagnostic purposes with the same Multiplex Amplicon
Quantiﬁcation assay.
Recessive genes are far less prominent in the subgroup of the
congenital cases with only two patients with mutations in PRX and
SH3TC2, respectively.
The second phenotypic subgroup consists of patients who dis-
play early and progressive delay in motor development in the ﬁrst
year, often in combination with early foot deformities after an
otherwise normal neonatal period. Recessive mutations in FGD4,
PRX, MTMR2, SBF2 and GDAP1 are strongly represented in this
subgroup. A few patients with dominant mutations in MPZ and
MFN2 further broaden the spectrum (Fig. 2).
The third phenotypic subgroup is largely overlapping with the
second and consists of patients with a CMT1A duplication pre-
senting with early and often congenital foot deformities, a more or
less normal early motor development and progressive gait difﬁcul-
ties later on in childhood. These patients represent the far end of
the severity spectrum of classical CMT1A. This ﬁnding underscores
the importance of ruling out the CMT1A duplication in any patient
with a demyelinating neuropathy, even in very young children
(Fig. 2).
The electrophysiological ﬁndings in our cohort show that early
onset hereditary neuropathies are more frequently of a demyeli-
nating type rather than axonal. Severe slowing of nerve conduc-
tion velocity is seen in patients with mutations in PRX and FGD4
and also in the myelin-associated genes MPZ, EGR and PMP22.A
more variable range of slowing in motor nerve conduction velocity
is observed in demyelinating neuropathies caused by mutations in
MTMR2, SBF2 and SH3TC2. Although axonal forms are propor-
tionally less common, early onset neuropathies cannot be re-
stricted to demyelinating neuropathies alone. We identiﬁed three
index patients with axonal neuropathies carrying mutations in
GDAP1 and MFN2. Of note is that a sural nerve biopsy performed
in Patient PN-860.03 (homozygous GDAP1 mutation) showed lim-
ited (secondary) demyelinating changes in addition to manifest
signs of axonal neuropathy (Nelis et al., 2002b). The direct com-
parison of the results of the nerve conduction studies presented
here is troublesome because of the broad range of ages at which
the electrophysiological exams were performed and the problem
of normative values in young children (Garcia et al., 2000).
However, the general trends in these electrophysiological ﬁndings
are clinically meaningful and hold true despite the above-
mentioned drawbacks. Thorough electrophysiological testing re-
mains the cornerstone of the diagnosis in the context of hereditary
neuropathies and should, in this particular instance, be performed
by electrophysiologists specialized in paediatric neuromuscular dis-
orders (Wilmshurst et al., 2003; Pitt, 2011). To differentiate from
metabolic diseases, routine screening should be performed such as
biochemical markers for lysosomal storage disorders in urine, very
long chain fatty acids, isoelectric focusing of serum transferine and
organic acids (Landrieu et al., 2011).
The current study focuses on patients with early onset forms of
hereditary motor and sensory neuropathy. Overlap with pure
motor forms (hereditary motor neuropathy) has been described,
however, especially in axonal forms of hereditary motor and sen-
sory neuropathy. In that context, it is important to note that re-
cently, MFN2 mutations were found in various patients with pure
motor phenotypes (Feely et al., 2011). Therefore, it may be useful
to extend future mutation screenings of MFN2 to patients with
early onset forms of hereditary motor neuropathy.
In general, nerve biopsies are considered invasive procedures
that are best avoided if a diagnosis can be established using
other methods. In this series, in 19 of 35 patients with proven
mutations, neuropathological examination of a sural nerve or
skin biopsy was performed. This indicates that such a procedure
Figure 2 Gene distribution for patients with a known pathogenic mutation in function of disease onset, inheritance pattern and
phenotypic subgroup. The x-axis represents the age at onset in months and years, the y-axis displays the estimated incidence of patients
with dominant (red line) and recessive (green line) subtypes of hereditary neuropathy. CONG = congenital onset phenotype characterized
by neonatal hypotonia   breathing and feeding difﬁculties; MMD = motor milestone delay phenotype with or without early foot
deformities and progressive delay in motor milestones within the ﬁrst year of life; m = month; y = year.
2674 | Brain 2011: 134; 2664–2676 J. Baets et al.may still be important in the diagnosis of hereditary neuropathies
in young children for a number of reasons (Vallat et al., 2011).
First, a nerve (and muscle) biopsy can be helpful in differentiating
peripheral neuropathy from other causes of severe hypotonia in
newborns. Secondly, patients with early onset neuropathies are
often isolated in their family, making the differentiation from
other rare acquired causes more difﬁcult, especially in the absence
of consanguinity among the parents. In addition, electrophysio-
logical testing may be inconclusive with regard to discerning
demyelinating from axonal forms due to technical limitations and
severe denervation (Wilmshurst et al., 2003). Finally, pathology
may unveil certain speciﬁc ﬁndings that can help to orient mo-
lecular testing. Myelin outfoldings and redundant myelin loops, for
example, are a conspicuous feature that suggests possible muta-
tions in the myotubularin genes MTMR2 and SBF2 (Nelis et al.,
2002a; Azzedine et al., 2003). However, these ﬁndings should be
interpreted cautiously, because in the current study, and in previ-
ous reports, similar changes were also observed in patients with
mutations in FGD4, SH3TC2, PRX and MPZ (Takashima et al.,
2002; Kochanski et al., 2004; Fabrizi et al., 2009; Houlden
et al., 2009). Basal lamina onion bulbs are in turn considered a
feature suggestive of SH3TC2 mutation carriers (Houlden et al.,
2009).
The current study contributes to our understanding of the clin-
ical and genetic basis of hereditary neuropathies with disease
onset in the ﬁrst year of life. A molecular diagnosis could be
reached in 45% of patients from a heterogeneous screening
cohort of 77 unrelated index patients leaving more than half of
the patients without genetic diagnosis to date. This further under-
scores the fact that other still unknown mutations must exist in
addition to yet unreported phenotypic variants associated with
known or unknown disease-associated genes.
Organizing rational molecular diagnostic testing in the speciﬁc
case of early onset neuropathies is cumbersome due to the low
mutation frequency per gene and the broad genetic heterogeneity
(Ryan and Ouvrier, 2005). Some directions can be drawn up
based on the ﬁndings of this study. In patients with a congenital
disease onset, mutations in dominant genes are more likely to be
the cause, while mutations in recessive genes are more probable in
patients with progressive delay in motor development in the ﬁrst
year of life, especially if parents are consanguineous. Axonal sub-
types are probably restricted to a smaller subset of genes that may
be tested preferentially. Other ﬁndings such as myelin outfoldings
on nerve pathology may help to prioritize molecular testing to
some extent. Likewise, severe and early scoliosis, although very
suggestive of SH3TC2 mutations (Houlden et al., 2009), may also
be seen in patients carrying mutations in other genes and can in
fact be considered a feature potentially to be found in many types
of severe and progressive neuropathy of early childhood.
In conclusion, reaching a correct genetic diagnosis in children
with severe early onset hereditary motor and sensory neuropathy
remains a major challenge with conventional screening techniques.
A future solution for this diagnostic conundrum may lie in the
more systematic diagnostic application of recently developed tech-
nologies for massive parallel sequencing. While operational costs
of these methods plummet, capacity and overall robustness grows
exponentially. These technologies allow for the simultaneous
screening of larger sets of genes and eventually of patient’s
entire exome or even genome (Hoischen et al., 2010; Lupski
et al., 2010; Montenegro et al., 2011). By doing so, mutations
in one of the myriad of known genes can be identiﬁed quickly and
also new genetic risk factors can be scrutinized on the same data-
sets. Such approaches would ultimately allow geneticists to base
the entire process of molecular diagnosis in a patient on a single
test. The downside of these technologies is that they will yield
numerous sequence variants of unknown signiﬁcance. Although
further validation of sequence variants in known genes may still
be relatively straightforward, the identiﬁcation of pathogenic mu-
tations in novel genes will be more problematic and will require
pooling of multiple unrelated patients and the use of robust bio-
informatics tools (Depristo et al., 2011).
Acknowledgements
We are grateful to the patients and their families for their willing-
ness to cooperate in this research project. We also wish to thank
the Genetic Service Facility (VIB) for the sequencing support
(http://www.vibgeneticservicefacility.be/).
Funding
University of Antwerp; Fund for Scientiﬁc Research
(FWO-Flanders); Medical Foundation Queen Elisabeth (GSKE);
‘Association Belge contre les Maladies Neuromusculaires’
(ABMM); Interuniversity Attraction Poles P6/43 programme of
the Belgian Federal Science Policy Ofﬁce (BELSPO); ‘Methusalem
excellence grant’ of the Flemish Government; Austrian Science
Fond (FWF; P19455-B05); PhD fellowships of the FWO-Flanders
(to J.B., M.Z. and K.P.); Bogazici University Research Fund
(00M102, in part).
References
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
et al. A method and server for predicting damaging missense muta-
tions. Nat Methods 2010; 7: 248–9.
Azzedine H, Bolino A, Taieb T, Birouk N, Di Duca M, Bouhouche A, et al.
Mutations in MTMR13, a new pseudophosphatase homologue of
MTMR2 and Sbf1, in two families with an autosomal recessive demye-
linating form of Charcot-Marie-Tooth disease associated with
early-onset glaucoma. Am J Hum Genet 2003; 72: 1141–53.
Bolino A, Muglia M, Conforti FL, LeGuern E, Salih MA, Georgiou DM,
et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene
encoding myotubularin-related protein-2. Nat Genet 2000; 25: 17–9.
Burns J, Ryan MM, Ouvrier RA. Evolution of foot and ankle manifest-
ations in children with CMT1A. Muscle Nerve 2009; 39: 158–66.
Ceuterick-de Groote C, De Jonghe P, Timmerman V, Van Goethem G,
Lofgren A, Ceulemans B, et al. Infantile demyelinating neuropathy
associated with a de novo point mutation on Ser72 in PMP22 and
basal lamina onion bulbs in skin biopsy. Pathol Res Pract 2001; 197:
193–8.
Connolly AM. Chronic inﬂammatory demyelinating polyneuropathy in
childhood. Pediatr Neurol 2001; 24: 177–82.
Genetic spectrum of infantile onset neuropathies Brain 2011: 134; 2664–2676 | 2675Depristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al.
A framework for variation discovery and genotyping using
next-generation DNA sequencing data. Nat Genet 2011; 43: 491–8.
Dierick I, Baets J, Irobi J, Jacobs A, De Vriendt E, Deconinck T, et al.
Relative contribution of mutations in genes for autosomal dominant
distal hereditary motor neuropathies: a genotype-phenotype correl-
ation study. Brain 2008; 131: 1217–27.
Dejerine J, Sottas J. Sur la nevrite interstitielle, hypertrophique et pro-
gressive de I’enfance. C R Soc Biol 1893; 45: 63–96.
Fabrizi GM, Taioli F, Cavallaro T, Ferrari S, Bertolasi L, Casarotto M, et al.
Further evidence that mutations in FGD4/frabin cause Charcot-Marie-
Tooth disease type 4H. Neurology 2009; 72: 1160–4.
Feely SM, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, et al.
MFN2 mutations cause severe phenotypes in most patients with
CMT2A. Neurology 2011; 76: 1690–6.
Gabreels-Festen A. Dejerine-Sottas syndrome grown to maturity: over-
view of genetic and morphological heterogeneity and follow-up of 25
patients. J Anat 2002; 200: 341–56.
Gabreels-Festen A, Thomas PK. Autosomal recessive hereditary motor
and sensory neuropathies. In: Dyck PJ, Thomas PK, editors.
Peripheral neuropathy. Philadelphia: Saunders; 2005. p. 1769–90.
Garcia A, Calleja J, Antolin FM, Berciano J. Peripheral motor and sensory
nerve conduction studies in normal infants and children. Clin
Neurophysiol 2000; 111: 513–20.
Hoischen A, Gilissen C, Arts P, Wieskamp N, van der Vliet W, Vermeer S,
et al. Massively parallel sequencing of ataxia genes after array-based
enrichment. Hum Mutat 2010; 31: 494–9.
Houlden H, Laura M, Ginsberg L, Jungbluth H, Robb SA, Blake J, et al.
The phenotype of Charcot-Marie-Tooth disease type 4C due to
SH3TC2 mutations and possible predisposition to an inﬂammatory
neuropathy. Neuromuscul Disord 2009; 19: 264–9.
Kochanski A, Drac H, Kabzinska D, Hausmanowa-Petrusewicz I. A novel
mutation, Thr65Ala, in the MPZ gene in a patient with Charcot-
Marie-Tooth type 1B disease with focally folded myelin.
Neuromuscul Disord 2004; 14: 229–32.
Landrieu P, Baets J, De Jonghe P. Hereditary motor-sensory, sensory and
motor neuropathies in childhood. In: Dulac O, Lassonde M, Sarnat H,
editors. Pediatric neurology handbook. Elsevier; 2011.
Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC,
Nazareth L, et al. Whole-genome sequencing in a patient with
Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362: 1181–91.
Montenegro G, Powell E, Huang J, Speziani F, Edwards YJ, Beecham G,
et al. Exome sequencing allows for rapid gene identiﬁcation in a
Charcot-Marie-Tooth family. Ann Neurol 2011; 69: 464–70.
Nelis E, Erdem S, Tan E, Lofgren A, Ceuterick C, De Jonghe P, et al. A
novel homozygous missense mutation in the myotubularin-related pro-
tein 2 gene associated with recessive Charcot-Marie-Tooth disease
with irregularly folded myelin sheaths. Neuromuscul Disord 2002a;
12: 869–73.
Nelis E, Erdem S, Van Den Bergh PY, Belpaire-Dethiou MC, Ceuterick C,
Van Gerwen V, et al. Mutations in GDAP1: autosomal recessive
CMT with demyelination and axonopathy. Neurology 2002b; 59:
1865–72.
Nelis E, Timmerman V, De Jonghe P, Muylle L, Martin JJ, Van
Broeckhoven C. Linkage and mutation analysis in an extended family
with Charcot-Marie-Tooth disease type 1B. J Med Genet 1994; 31:
811–5.
Nicholson GA, Magdelaine C, Zhu D, Grew S, Ryan MM, Sturtz F, et al.
Severe early-onset axonal neuropathy with homozygous and
compound heterozygous MFN2 mutations. Neurology 2008; 70:
1678–81.
Parman Y, Battaloglu E, Baris I, Bilir B, Poyraz M, Bissar-Tadmouri N,
et al. Clinicopathological and genetic study of early-onset demyelinat-
ing neuropathy. Brain 2004; 127: 2540–50.
Phillips JP, Warner LE, Lupski JR, Garg BP. Congenital hypomyelinating
neuropathy: two patients with long-term follow-up. Pediatr Neurol
1999; 20: 226–32.
Pitt M. Paediatric electromyography in the modern world: a personal
view. Dev Med Child Neurol 2011; 53: 120–4.
Pitt M, Houlden H, Jacobs J, Mok Q, Harding B, Reilly M, et al. Severe
infantile neuropathy with diaphragmatic weakness and its relationship
to SMARD1. Brain 2003; 126: 2682–92.
Plante-Bordeneuve V, Said G. Dejerine-Sottas disease and hereditary
demyelinating polyneuropathy of infancy. Muscle Nerve 2002; 26:
608–21.
Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE,
Baas F, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-
Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative
Research Group. Neuromuscul Disord 1991; 1: 93–7.
Rotthier A, Baets J, Vriendt ED, Jacobs A, Auer-Grumbach M, Levy N,
et al. Genes for hereditary sensory and autonomic neuropathies: a
genotype-phenotype correlation. Brain 2009; 132: 2699–711.
Rozen S, Skaletsky H. Primer3 on the WWW for general users and for
biologist programmers. Methods Mol Biol 2000; 132: 365–86.
Ryan MM, Ouvrier R. Hereditary peripheral neuropathies of childhood.
Curr Opin Neurol 2005; 18: 105–10.
Scherer SS. Finding the causes of inherited neuropathies. Arch Neurol
2006; 63: 812–6.
Senderek J, Bergmann C, Stendel C, Kirfel J, Verpoorten N, De Jonghe P,
et al. Mutations in a gene encoding a novel SH3/TPR domain protein
cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy.
Am J Hum Genet 2003; 73: 1106–19.
Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J,
et al. APP duplication is sufﬁcient to cause early onset Alzheimer’s
dementia with cerebral amyloid angiopathy. Brain 2006; 129:
2977–83.
Smit LS, Roofthooft D, van Ruissen F, Baas F, van Doorn PA. Congenital
hypomyelinating neuropathy, a long term follow-up study in an af-
fected family. Neuromuscul Disord 2008; 18: 59–62.
Sorour E, MacMillan J, Upadhyaya M. Novel mutation of the myelin P0
gene in a CMT1B family. Hum Mutat 1997; 9: 74–7.
Stendel C, Roos A, Deconinck T, Pereira J, Castagner F, Niemann A,
et al. Peripheral nerve demyelination caused by a mutant Rho
GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J
Hum Genet 2007; 81: 158–64.
Takashima H, Boerkoel CF, De Jonghe P, Ceuterick C, Martin JJ, Voit T,
et al. Periaxin mutations cause a broad spectrum of demyelinating
neuropathies. Ann Neurol 2002; 51: 709–15.
Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A,
Nelis E, et al. Novel missense mutation in the early growth response
2 gene associated with Dejerine-Sottas syndrome phenotype.
Neurology 1999; 52: 1827–32.
Vallat JM, Funalot B, Magy L. Nerve biopsy: requirements for diagnosis
and clinical value. Acta Neuropathol 2011; 121: 313–26.
Wilmshurst JM, Pollard JD, Nicholson G, Antony J, Ouvrier R. Peripheral
neuropathies of infancy. Dev Med Child Neurol 2003; 45: 408–14.
Yoshihara T, Yamamoto M, Hattori N, Misu K, Mori K, Koike H, et al.
Identiﬁcation of novel sequence variants in the neuroﬁlament-light
gene in a Japanese population: analysis of Charcot-Marie-Tooth dis-
ease patients and normal individuals. J Peripher Nerv Syst 2002; 7:
221–4.
Yum SW, Zhang J, Mo K, Li J, Scherer SS. A novel recessive Neﬂ mu-
tation causes a severe, early-onset axonal neuropathy. Ann Neurol
2009; 66: 759–70.
Zhang F, Seeman P, Liu P, Weterman MA, Gonzaga-Jauregui C,
Towne CF, et al. Mechanisms for nonrecurrent genomic rearrange-
ments associated with CMT1A or HNPP: rare CNVs as a cause for
missing heritability. Am J Hum Genet 2010; 86: 892–903.
Zimon M, Baets J, Auer-Grumbach M, Berciano J, Garcia A, Lopez-
Laso E, et al. Dominant mutations in the cation channel gene transient
receptor potential vanilloid 4 cause an unusual spectrum of neuropa-
thies. Brain 2010; 133: 1798–809.
Zimon M, Baets J, Fabrizi GM, Jaakkola E, Kabzin ´ska D, Pilch J, et al.
Dominant GDAP1 mutations cause predominantly mild CMT pheno-
types. Neurology 2011 Jul 13. [Epub ahead of print].
2676 | Brain 2011: 134; 2664–2676 J. Baets et al.